Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOXIRI vs Doublet Regimen in Metastatic Colorectal Cancer
NCT05316818Phase 2Completed
- Sponsor
- Kasr Al Ainy Hospital
- Start
- Jan 2018
- Primary completion
- Dec 2020
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan, oxaliplatin, fluorouracil and folinic acid in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Kasr Al Ainy Hospital. Primary endpoints: Overall Response Rate at 6 months and Rate of Adverse Events. Started Jan 2018; status: completed.
02
Drugs
irinotecanoxaliplatinfluorouracilfolinic acid
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05316818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05316818.